Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease

CD133+ cells are mobilized into the circulation following a single injection of the CXCR4 antagonist plerixafor, without clear evidence for systemic activation of inflammation. This effect may be of importance in cell-based approaches for treating cardiovascular diseases.